Abstract
Palliative bone radiation is the predominant skeletal-related event (SRE) reported in prostate cancer. Bone targeted agents (BTA), such as denosumab and zoledronic acid, are shown to prevent and delay SREs. This study evaluated real-world use of BTA in relation to palliative bone radiation prior to prostate-cancer related death using linked provincial databases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
